Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
Refine your Search
|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Teva Pharmaceutical Industries Ltd-Deals & Alliances Report
|
Mar 2011 |
£380 |
100% |
|
Teva Pharmaceutical Industries Ltd-Detailed Product Pipeline
|
Mar 2011 |
£475 |
97% |
|
Biosimilars
|
Feb 2011 |
£2,845 |
89% |
|
Lou Gehrig's Disease
|
Apr 2010 |
£2,180 |
81% |
Neutropenia - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
80% |
Allergic Rhinitis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
79% |
Rhinitis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
79% |
Nippon Kayaku Co., Ltd. – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
78% |
The World Generic Market Report
2011
|
Feb 2011 |
£795 |
77% |
Biosimilars Approval Pathways in the US and Europe
Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
|
Apr 2011 |
£2,215 |
77% |
Manufacturing of Solid Dosage Forms
2011
|
Feb 2011 |
£2,215 |
77% |
The Future of Biosimilars
Market Forecasts to 2015
|
Dec 2009 |
£2,215 |
76% |
Innovative R&D Strategies and Models
Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs
|
Sep 2011 |
£2,215 |
75% |
|
Opportunities and Challenges for Generic Drugs in the UK 2007
|
Jun 2007 |
£795 |
75% |
Multiple Sclerosis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
75% |
Women's Infertility Therapeutics
PipelineAssessment and Market Forecasts to 2018
|
Sep 2011 |
£2,215 |
74% |
|
Anticoagulants
|
Sep 2010 |
£2,845 |
74% |
Infertility - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
74% |
Migraine - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
74% |
|
CNS Therapeutics
|
May 2008 |
£2,500 |
73% |
|
Therapeutics for Memory and Cognition Disorders
|
Apr 2009 |
£3,065 |
72% |
Bone and Joint Infection Market to 2016
Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment
|
Feb 2011 |
£2,215 |
72% |
Motor Neurone Diseases - Pipeline Review
H2 2011
|
Aug 2011 |
£315 |
71% |
|
Psoriasis Drugs
|
Apr 2010 |
£2,500 |
71% |
Delivering New Biopharmaceutical Therapies
Challenges & Opportunities
|
Jan 2009 |
£945 |
71% |
|
Contraceptives
|
Oct 2010 |
£2,845 |
70% |
Overactive Bladder - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
70% |
Astrocytoma - Pipeline Review
Q2 2011
|
Apr 2011 |
£315 |
70% |
Chemotherapy Effects - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
70% |
Amyotrophic Lateral Sclerosis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
70% |
